Study of NM8074 in Adult C3 Glomerulopathy Patients
NCT05647811
·
clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
NOT_YET_RECRUITING
Status
18
Enrollment
INDUSTRY
Sponsor class
Conditions
C3 Glomerulopathy
Interventions
DRUG:
NM8074
Sponsor
NovelMed Therapeutics